Pulmovant to present Phase 2 mosliciguat results at ERS Congress

September 6, 2026 1:00 AM

Pulmovant, a subsidiary of Roivant Sciences (NASDAQ: ROIV), announced that topline results from its Phase 2 PHocus study of mosliciguat ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found